Clinical trial

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

NCT00729742

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Comparator: erlotinib + dalotuzumab Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Comparator: erlotinib monotherapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-02-01

PhasePHASE1

Conditions

Carcinoma, Non-small Cell Lungunresolved

Interventions

Comparator: erlotinib + dalotuzumabDRUG

Comparator: erlotinib monotherapyDRUG

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00729742 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.